3 No-Brainer Stocks to Buy in July

Don't let the summer heat keep you from making money

July is a great time to invest in the stocks of top-tier companies

Three Motley Fool contributors think they've found no-brainer stocks to buy this month

Image source: Getty Images

Something for every investor Keith Speights (AbbVie): Growth investors typically aren't interested in the stocks that are appealing to income investors or value investors

However, I think there's one stock to buy in July that offers something for every investor: big drugmaker AbbVie

Income investors should love AbbVie

It's a Dividend King with an impressive 53 consecutive years of dividend increases

The pharmaceutical giant's forward dividend yield is also a juicy 3

AbbVie's s trade below 15. 6 times forward earnings

Perhaps most intriguing, though, is AbbVie's super-low price-to-earnings-to-growth (PEG) ratio of 0. 4, based on five-year earnings growth jections of analysts surveyed by LSEG

That brings us to what AbbVie offers for growth investors

Granted, the company isn't poised to der the jaw-dropping levels of growth that some stocks might

However, AbbVie should hold its own, thanks to fast-growing therapies including Rinvoq and Skyrizi

With its dividends added to the mix, I predict that this pharma stock will der market-beating total returns over the next several years

Eli Lilly stock could be overdue for a big rally David Jagielski (Eli Lilly): One growth beast that continues to be an attractive buy this year is Eli Lilly

While some investors may be worried growing competition in the GLP-1 space, Eli Lilly has established itself as a leader there, with two fantastic ducts in Zepbound for weight loss and Mounjaro for diabetes

A lot of healthcare companies are weight loss drugs, but it's by no means easy to do so

Pfizer stopped the development of its daily weight loss pill after a trial participant experienced a r injury

And Amgen recently released phase 2 trial results for its monthly treatment, MariTide, where tolerability was a blem

Meanwhile, Eli Lilly also has a diverse that goes beyond just weight loss

Last year, for example, it obtained apval for an Alzheimer's drug, Kisunla, which has the potential to be yet another blockbuster for the

With solid results such as these and the still on the cusp of much more growth, Eli Lilly is a no-brainer buy right now given all the potential it possesses

Although its stock is trading at more than 60 times its trailing earnings, the premium looks to be well worth it

New era, same results sper Junior Bakiny (Vertex Pharmaceuticals): Over the past decade, Vertex Pharmaceuticals, a leading bio, has generated excellent financial results and market-beating returns, thanks to its work in cystic fibrosis (CF)

The drugmaker owns the only therapies that address the underlying causes of this rare disease

Vertex is still making breakthroughs in its core area

Late last year, it earned apval for Alyftrek, a next-gen CF medicine

However, Vertex Pharmaceuticals has entered a new era, one where it has a more diversified lineup

Meanwhile, Vertex Pharmaceuticals plans on submitting regulatory applications for zimislecel, an investigational therapy for type 1 diabetes, next year

Furthermore, Vertex Pharmaceuticals has other non-CF candidates in various stages of development

The bio still has room to grow in its central therapeutic area, but these new apvals in different fields have arguably made the stock even more attractive

Here's what I expect from Vertex Pharmaceuticals in the next five years

The drugmaker will make significant clinical gress and earn at least one brand-new apval and ly several label expansions

Vertex Pharmaceuticals should also continue dering consistent revenue and earnings growth

Although the company's s fell because of somewhat disappointing first-quarter results, Vertex Pharmaceuticals' long-term spects look incredibly attractive

The stock appears to be a no-brainer buy today

David Jagielski has no position in any of the stocks mentioned

Keith Speights has positions in AbbVie and Vertex Pharmaceuticals

Sper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals

The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals

The Motley Fool has a disclosure policy.